Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
Thierry André(Inserm), Sara Lonardi(Istituto Oncologico Veneto), Ming Lei(Bristol-Myers Squibb (United States)), Tian Chen(Sorbonne Université), Michael Schenker(Sorbonne Université), Jaafar Bennouna(Hôpital Foch), María Luisa Limón(Sorbonne Université), Guillermo Méndez(Sorbonne Université), Lars Henrik Jensen(Sorbonne Université), Elvis Cela(Sorbonne Université), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Timuçin Çil(Sorbonne Université), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Giampaolo Tortora(University of Naples Federico II), Myriam Chalabi(Oncode Institute), Christelle de la Fouchardière(Aix-Marseille Université), Takayuki Yoshino(University of Tsukuba), Maria Ignez Braghiroli(Twitter (United States)), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jin Li(Hainan Medical University), Matthew Dixon(Sorbonne Université), Rohit Joshi(Sorbonne Université), Elena Élez(Vall d'Hebron Hospital Universitari), Sandzhar Abdullaev(Bristol-Myers Squibb (United States)), Laëtitia Dahan, José Luis Manzano Mozo(Sorbonne Université), Eray Goekkurt(Sorbonne Université)
Cited by 208
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k